Accordingly, selective AT1-receptor blockade with protective nature of AT2R signaling is an ideal therapeutic option for MFS patients, and recent clinical trials have shown that the inhibitory effect of losartan on the growth of aortic aneurysms is equivalent to β-blockers [4,42,43,44]. Here, AGTR1 is linked to aortic aneurysm.